Detrended Fluctuation Analysis in the prediction of type 2 diabetes mellitus in patients at risk: Model optimization and comparison with other metrics

[EN] Complexity analysis of glucose time series with Detrended Fluctuation Analysis (DFA) has been proved to be useful for the prediction of type 2 diabetes mellitus (T2DM) development. We propose a modified DFA algorithm, review some of its characteristics and compare it with other metrics derived from continuous glucose monitorization in this setting. Several issues of the DFA algorithm were evaluated: (1) Time windowing: the best predictive value was obtained including all time-windows from 15 minutes to 24 hours. (2) Influence of circadian rhythms: for 48-hour glucometries, DFA alpha scaling exponent was calculated on 24hour sliding segments (1-hour gap, 23-hour overlap), with a median coefficient of variation of 3.2%, which suggests that analysing time series of at least 24-hour length avoids the influence of circadian rhythms. (3) Influence of pretreatment of the time series through integration: DFA without integration was more sensitive to the introduction of white noise and it showed significant predictive power to forecast the development of T2DM, while the pretreated time series did not. (4) Robustness of an interpolation algorithm for missing values: The modified DFA algorithm evaluates the percentage of missing values in a time series. Establishing a 2% error threshold, we estimated the number and length of missing segments that could be admitted to consider a time series as suitable for DFA analysis. For comparison with other metrics, a Principal Component Analysis was performed and the results neatly tease out four different components. The first vector carries information concerned with variability, the second represents mainly DFA alpha exponent, while the third and fourth vectors carry essentially information related to the two "pre-diabetic behaviours" (impaired fasting glucose and impaired glucose tolerance). The scaling exponent obtained with the modified DFA algorithm proposed has significant predictive power for the development of T2DM in a high-risk population compared with other variability metrics or with the standard DFA algorithm.This study has been funded by Instituto de Salud Carlos III through the project PI17/00856 (Co-funded by the European Regional Development Fund, A way to make Europe). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Colás, A.; Vigil, L.; Vargas, B.; Cuesta Frau, D.; Varela, M. (2019). Detrended Fluctuation Analysis in the prediction of type 2 diabetes mellitus in patients at risk: Model optimization and comparison with other metrics. PLoS ONE. 14(12):1-15. https://doi.org/10.1371/journal.pone.0225817S1151412Goldstein, B., Fiser, D. H., Kelly, M. M., Mickelsen, D., Ruttimann, U., & Pollack, M. M. (1998). Decomplexification in critical illness and injury: Relationship between heart rate variability, severity of illness, and outcome. Critical Care Medicine, 26(2), 352-357. doi:10.1097/00003246-199802000-00040Varela, M. (2008). The route to diabetes: Loss of complexity in the glycemic profile from health through the metabolic syndrome to type 2 diabetes. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Volume 1, 3-11. doi:10.2147/dmso.s3812Vikman, S., Mäkikallio, T. H., Yli-Mäyry, S., Pikkujämsä, S., Koivisto, A.-M., Reinikainen, P., … Huikuri, H. V. (1999). Altered Complexity and Correlation Properties of R-R Interval Dynamics Before the Spontaneous Onset of Paroxysmal Atrial Fibrillation. Circulation, 100(20), 2079-2084. doi:10.1161/01.cir.100.20.2079Wang, H., Naghavi, M., Allen, C., Barber, R. M., Bhutta, Z. A., Carter, A., … Coates, M. M. (2016). Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. The Lancet, 388(10053), 1459-1544. doi:10.1016/s0140-6736(16)31012-1Saudek, C. D., Derr, R. L., & Kalyani, R. R. (2006). Assessing Glycemia in Diabetes Using Self-monitoring Blood Glucose and Hemoglobin A1c. JAMA, 295(14), 1688. doi:10.1001/jama.295.14.1688Monnier, L., Colette, C., & Owens, D. R. (2008). Glycemic Variability: The Third Component of the Dysglycemia in Diabetes. Is it Important? How to Measure it? Journal of Diabetes Science and Technology, 2(6), 1094-1100. doi:10.1177/193229680800200618Abdul-Ghani, M. A., Tripathy, D., & DeFronzo, R. A. (2006). Contributions of  -Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose. Diabetes Care, 29(5), 1130-1139. doi:10.2337/dc05-2179(2017). 2. Classification and Diagnosis of Diabetes:Standards of Medical Care in Diabetes—2018. Diabetes Care, 41(Supplement 1), S13-S27. doi:10.2337/dc18-s002Tabák, A. G., Herder, C., Rathmann, W., Brunner, E. J., & Kivimäki, M. (2012). Prediabetes: a high-risk state for diabetes development. The Lancet, 379(9833), 2279-2290. doi:10.1016/s0140-6736(12)60283-9DeFronzo, R. A., Banerji, M. A., Bray, G. A., Buchanan, T. A., Clement, S., … Tripathy, D. (2009). Determinants of glucose tolerance in impaired glucose tolerance at baseline in the Actos Now for Prevention of Diabetes (ACT NOW) study. Diabetologia, 53(3), 435-445. doi:10.1007/s00125-009-1614-2Nathan, D. M., Davidson, M. B., DeFronzo, R. A., Heine, R. J., Henry, R. R., Pratley, R., & Zinman, B. (2007). Impaired Fasting Glucose and Impaired Glucose Tolerance: Implications for care. Diabetes Care, 30(3), 753-759. doi:10.2337/dc07-9920Ogata, H., Tokuyama, K., Nagasaka, S., Tsuchita, T., Kusaka, I., Ishibashi, S., … Yamamoto, Y. (2012). The lack of long-range negative correlations in glucose dynamics is associated with worse glucose control in patients with diabetes mellitus. Metabolism, 61(7), 1041-1050. doi:10.1016/j.metabol.2011.12.007Kohnert, K.-D. (2015). Utility of different glycemic control metrics for optimizing management of diabetes. World Journal of Diabetes, 6(1), 17. doi:10.4239/wjd.v6.i1.17García Maset, L., González, L. B., Furquet, G. L., Suay, F. M., & Marco, R. H. (2016). Study of Glycemic Variability Through Time Series Analyses (Detrended Fluctuation Analysis and Poincaré Plot) in Children and Adolescents with Type 1 Diabetes. Diabetes Technology & Therapeutics, 18(11), 719-724. doi:10.1089/dia.2016.0208Service, F. J., O’Brien, P. C., & Rizza, R. A. (1987). Measurements of Glucose Control. Diabetes Care, 10(2), 225-237. doi:10.2337/diacare.10.2.225Goldberger, A. L., Amaral, L. A. N., Hausdorff, J. M., Ivanov, P. C., Peng, C.-K., & Stanley, H. E. (2002). Fractal dynamics in physiology: Alterations with disease and aging. Proceedings of the National Academy of Sciences, 99(Supplement 1), 2466-2472. doi:10.1073/pnas.012579499Crenier, L., Lytrivi, M., Van Dalem, A., Keymeulen, B., & Corvilain, B. (2016). Glucose Complexity Estimates Insulin Resistance in Either Nondiabetic Individuals or in Type 1 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 101(4), 1490-1497. doi:10.1210/jc.2015-4035Rodríguez de Castro, C., Vigil, L., Vargas, B., García Delgado, E., García Carretero, R., Ruiz-Galiana, J., & Varela, M. (2016). Glucose time series complexity as a predictor of type 2 diabetes. Diabetes/Metabolism Research and Reviews, 33(2), e2831. doi:10.1002/dmrr.2831Weber, C., & Schnell, O. (2009). The Assessment of Glycemic Variability and Its Impact on Diabetes-Related Complications: An Overview. Diabetes Technology & Therapeutics, 11(10), 623-633. doi:10.1089/dia.2009.0043Pincus, S. M., Gladstone, I. M., & Ehrenkranz, R. A. (1991). A regularity statistic for medical data analysis. Journal of Clinical Monitoring, 7(4), 335-345. doi:10.1007/bf01619355Richman, J. S. (2007). Sample Entropy Statistics and Testing for Order in Complex Physiological Signals. Communications in Statistics - Theory and Methods, 36(5), 1005-1019. doi:10.1080/03610920601036481Platiša, M. M., Bojić, T., Pavlović, S. U., Radovanović, N. N., & Kalauzi, A. (2016). Generalized Poincaré Plots-A New Method for Evaluation of Regimes in Cardiac Neural Control in Atrial Fibrillation and Healthy Subjects. Frontiers in Neuroscience, 10. doi:10.3389/fnins.2016.00038García-Puig, J., Ruilope, L. M., Luque, M., Fernández, J., Ortega, R., & Dal-Ré, R. (2006). Glucose Metabolism in Patients with Essential Hypertension. The American Journal of Medicine, 119(4), 318-326. doi:10.1016/j.amjmed.2005.09.010Lepot, M., Aubin, J.-B., & Clemens, F. (2017). Interpolation in Time Series: An Introductive Overview of Existing Methods, Their Performance Criteria and Uncertainty Assessment. Water, 9(10), 796. doi:10.3390/w9100796Eke, A., Hermán, P., Bassingthwaighte, J., Raymond, G., Percival, D., Cannon, M., … Ikrényi, C. (2000). Physiological time series: distinguishing fractal noises from motions. Pflügers Archiv - European Journal of Physiology, 439(4), 403-415. doi:10.1007/s004249900135Eke, A., Herman, P., Kocsis, L., & Kozak, L. R. (2002). Fractal characterization of complexity in temporal physiological signals. Physiological Measurement, 23(1), R1-R38. doi:10.1088/0967-3334/23/1/201King, A. B., Philis-Tsimikas, A., Kilpatrick, E. S., Langbakke, I. H., Begtrup, K., & Vilsbøll, T. (2017). A Fixed Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) Reduces Glycemic Fluctuation and Brings More Patients with Type 2 Diabetes Within Blood Glucose Target Ranges. Diabetes Technology & Therapeutics, 19(4), 255-264. doi:10.1089/dia.2016.0405Colas, A., Vigil, L., Rodríguez de Castro, C., Vargas, B., & Varela, M. (2018). New insights from continuous glucose monitoring into the route to diabetes. Diabetes/Metabolism Research and Reviews, 34(5), e3002. doi:10.1002/dmrr.3002Henriques, T., Munshi, M. N., Segal, A. R., Costa, M. D., & Goldberger, A. L. (2014). «Glucose-at-a-Glance». Journal of Diabetes Science and Technology, 8(2), 299-306. doi:10.1177/1932296814524095Hinton, P. R. (2004). Statistics Explained. doi:10.4324/9780203496787Van Cauter, E., Blackman, J. D., Roland, D., Spire, J. P., Refetoff, S., & Polonsky, K. S. (1991). Modulation of glucose regulation and insulin secretion by circadian rhythmicity and sleep. Journal of Clinical Investigation, 88(3), 934-942. doi:10.1172/jci115396Qian, J., & Scheer, F. A. J. L. (2016). Circadian System and Glucose Metabolism: Implications for Physiology and Disease. Trends in Endocrinology & Metabolism, 27(5), 282-293. doi:10.1016/j.tem.2016.03.00

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

All-Trans retinoic acid-induced thrombocytosis in a patient with acute promyelocytic leukaemia

Contains fulltext : 24535___.PDF (publisher's version ) (Open Access

A case of rapidly fatal systemic capillary leak syndrome in a kidney transplant recipient

Idiopathic Systemic Capillary Leak Syndrome (SCLS) is a rare entity characterised by idiopathic increasing of capillary permeability associated with recurrent attacks of hypovolaemic shock. We report the case of a 33-year-old man with a SCLS fourteen years after a cadaveric renal transplantation. The clinical evolution was rapidly fatal despite treatment with corticoids, aminophylline and terbutaline which are tile most efficient drugs known to prevent attacks.SCOPUS: ar.jinfo:eu-repo/semantics/publishe